Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

South Korea Extends Task Force To Crack Down On Illegal Kickbacks

This article was originally published in PharmAsia News

Executive Summary

The team of prosecutors, health ministry officials and Korea FDA officials was renewed for one more year to investigate the deep-rooted practice in the pharma and device sectors.

You may also be interested in...



Korea's Antitrust Watchdog Says Rebates Continuing Despite New Law; Levies $11 Million In Fines

SEOUL - South Korea's antitrust watchdog the Fair Trade Commission said rebates by both multinational and local Korean pharmaceutical companies are continuing even though doctors can be punished for accepting rebates under a new law that took effect late last year

Korean Government Launches Strongest-ever Drive To Root Out Rebates

SEOUL - In the strongest ever all-out government crackdown on rebates between hospital doctors and pharmaceutical companies, the Korean government established a joint task force at a Seoul Prosecution Office that it hopes will add teeth to better enforce anti-rebate laws implemented last November

Korea Targets Biologics, Devices, Health Care Among Economic Growth Projects For Next Decade

SEOUL - South Korean President Lee Myung-bak named "17 new growth engines" at a science and technology council meeting at his office in Seoul Jan. 13. Expected to spearhead the country's economic growth for the next 10 years, of those 17 economic growth engines, the Korean government targeted biologics, medical devices and global health care among the national priorities

Topics

UsernamePublicRestriction

Register

SC080239

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel